In both AOCS and TCGA 1 cohorts, high TSHZ3 expression was associated with the C1 molecular subtype, which is characterized by intense tumour stromal and epithelial–mesenchymal transition gene expression signatures and poor clinical outcome. The gene discussed is TSHZ3; the disease is neoplasm.